Radiation Protection Optimisation in Nuclear Medicine: Therapeutic Procedures

  • Jim MaloneEmail author
  • Geraldine O’Reilly
Conference paper
Part of the NATO Science for Peace and Security Series B: Physics and Biophysics book series (NAPSB, volume 1)


Radionuclide therapy has entered a phase in which there is growing interest, with new radionuclides, new labelling techniques and new molecular agents to assist targeting disease sites. This, among other developments, has given rise to questioning of some practices that have become enshrined in radionuclide therapy. In particular the issues around release of the patient back to their community and family has been the subject of much debate. This area will be reviewed and some aspects of unsealed source therapy which may be conducted in a general hospital will be described to illustrate the problems involved and some approaches to their solution.


Radionuclide therapy 131-I therapy Patient release from hospital Facility design for radionuclide therapy 


  1. 1.
    ICRP (2004). International Commission on Radiological Protection, Release of Patients After Radionuclide Therapy, Publication 94. Oxford, Elsevier.Google Scholar
  2. 2.
    NCRP (2006). National Council on Radiation Protection and measurements. Report 155: Management of radionuclide therapy patients. Bethesda, MD, NCRP.Google Scholar
  3. 3.
    EC (1998). European Commission, Radiation Protection 97, Radiation Protection Following Iodine-131: Luxembourg, European Commission.Google Scholar
  4. 4.
    RCP (2007). Royal College of Physicians, Radioiodine in the management of benign thyroid disease, Clinical guidelines, Report of a Working Party. London, RCP.Google Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  1. 1.Department of Medical Physics and BioengineeringTrinity College/St James’s HospitalDublin 8Ireland

Personalised recommendations